CGEMCullinan Oncology, Inc.

Nasdaq cullinanoncology.com


$ 27.30 $ -1.06 (-3.74 %)    

Thursday, 02-May-2024 11:34:54 EDT
QQQ $ 423.79 $ -1.49 (-0.35 %)
DIA $ 380.39 $ -1.21 (-0.32 %)
SPY $ 502.15 $ -2.25 (-0.45 %)
TLT $ 88.60 $ 0.38 (0.43 %)
GLD $ 213.28 $ 0.82 (0.39 %)
$ 28.1
$ 28.36
$ 0.00 x 0
$ 27.20 x 100
$ 27.20 - $ 28.36
$ 7.64 - $ 29.12
1,442,282
na
1.17B
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-09-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-17-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stifel-initiates-coverage-on-cullinan-therapeutics-with-buy-rating-announces-price-target-of-40

Stifel analyst Bradley Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Pric...

 why-is-cullinan-therapeutics-stock-trading-higher-on-wednesday

Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN...

 cullinan-therapeutics-to-present-clinical-data-from-phase-1-study-evaluating-novel-anti-micab-antibody-cln-619-as-monotherapy-and-in-combination-with-a-checkpoint-inhibitor-in-patients-with-advanced-solid-tumors-at-asco-2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today a...

 why-travelers-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

 btig-maintains-buy-on-cullinan-oncology-raises-price-target-to-30

BTIG analyst Kaveri Pohlman maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and raises the price target from $20 to $30.

 united-airlines-reports-upbeat-results-joins-childrens-place-interactive-brokers-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday.

 hc-wainwright--co-maintains-buy-on-cullinan-oncology-lowers-price-target-to-29

HC Wainwright & Co. analyst Edward White maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and lowers the price targe...

 why-skillsoft-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter...

 cullinan-shifts-focus-from-oncology-to-autoimmune-disorders-raises-280m-via-equity

Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show p...

 hc-wainwright--co-maintains-buy-on-cullinan-oncology-lowers-price-target-to-29

HC Wainwright & Co. analyst Edward White maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and lowers the price targe...

 unitedhealth-reports-upbeat-earnings-joins-cullinan-oncology-ericsson-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday.

Core News & Articles
Market-Moving news for April 16th
04/16/2024 12:36:44

CGEM: 23% | Cullinan Therapeutics To Pursue Development Of CLN-978 In Autoimmune Diseases, With Systemic Lupus Erythematosus As...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION